Jump to ContentJump to Main Navigation
Show Summary Details
More options …

International Journal of Adolescent Medicine and Health

Editor-in-Chief: Merrick, Joav

Editorial Board: Birch, Diana ML / Blum, Robert W. / Greydanus, MD, Dr. HC (Athens), Donald E. / Hardoff, Daniel / Kerr, Mike / Levy, Howard B / Morad, Mohammed / Omar, Hatim A. / de Paul, Joaquin / Rydelius, Per-Anders / Shek, Daniel T.L. / Sher, Leo / Silber, Tomas J. / Towns, Susan / Urkin, Jacob / Verhofstadt-Deneve, Leni / Zeltzer, Lonnie / Tenenbaum, Ariel


CiteScore 2018: 0.79

SCImago Journal Rank (SJR) 2018: 0.350
Source Normalized Impact per Paper (SNIP) 2018: 0.476

Online
ISSN
2191-0278
See all formats and pricing
More options …
Ahead of print

Issues

Pelvic inflammatory disease: management requires a patient, prudent, prejudice-free provider

Donald E. Greydanus
  • Corresponding author
  • Founding Chair and Professor, Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker MD School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008-1284, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joav Merrick
  • Professor of Pediatrics, Department of Pediatrics, Mt Scopus Campus, Hadassah Hebrew University Medical Center and Director, National Institute of Child Health and Human Development, Jerusalem, Israel
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria Demma Cabral
  • Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker MD School of Medicine, Kalamazoo, MI 49008-1284, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-11-13 | DOI: https://doi.org/10.1515/ijamh-2018-0216

References

  • [1]

    Greydanus DE, Dodich C. Pelvic inflammatory disease: a poignant, perplexing, potentially preventable problem for patients and physicians. Curr Opin Pediatr. 2015;27(1):92–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [2]

    Ford GW, Decker CF. Pelvic inflammatory disease. Dis Mon. 2016;62(8):301–5.CrossrefWeb of SciencePubMedGoogle Scholar

  • [3]

    Eliscu AH, Terrell LR, Blythe MJ, Burstein GR. Adolescent sexually transmitted infections. In: Omar HA, Greydanus DE, Tsitsika AK, Patel DR, Merrick J, editors. Pediatric and adolescent sexuality and gynecology: principles for the primary care clinician. New York: Nova Science; 2010. p. 567–75.Google Scholar

  • [4]

    Greydanus DE, Seyler J, Omar HA. Sexually transmitted diseases (STDs). In: Greydanus DE, Patel DR, Omar HA, Feucht C, Merrick J, editors. Adolescent medicine: pharmacotherapeutics in general, mental, and sexual health. Berlin: De Gruyter; 2012. p. 337–40.Google Scholar

  • [5]

    CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR. 2015;64:1–137.PubMedGoogle Scholar

  • [6]

    STAT. WHO issues new STD treatment guidelines as antibiotic resistance looms. URL: https://www.statnews.com/2016/08/30/stds-gonorrhea-who-guidelines.

  • [7]

    Matsuoka LY. History. In: Parish LC, Gschnait F, editors. Sexually transmitted diseases. New York: Springer; 1989.Google Scholar

  • [8]

    Greydanus DE, Merrick J. Medical history: some new perspectives, second Edition. New York: Nova Biomedical; 2018.Google Scholar

  • [9]

    Carpenter CM, Bahn JM. Adaptability to gonococcus to four bacteriostatic agents, sodium sulfathiazole, rivanol lactate, promin, and penicillin. Proc Soc Exp Biol Med. 1945;60:168–71.PubMedCrossrefGoogle Scholar

  • [10]

    Hecht H. Treatment of sulfathiazole-resistant-cases of gonorrhea. Urol Cutaneous Rev. 1946;50:85–8.PubMedGoogle Scholar

  • [11]

    Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, et al. Neisseria gonorrhoeae isolate surveillance project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65(7):1–19.PubMedCrossrefGoogle Scholar

  • [12]

    Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016;4(3). DOI: .CrossrefWeb of ScienceGoogle Scholar

  • [13]

    Barbee LA, Soge OO, Katz DA, Dombrowski JC, Holmes KK, Golden MR. Increases in Neisseria gonorrhoeae with reduced susceptibility to azithromycin among men who have sex with men in Seattle, King Country, Washington, 2012–2016. Clin Infect Dis. 2018;66(5):712–8.CrossrefGoogle Scholar

  • [14]

    Darville T. Recognition and treatment of chlamydial infections from birth to adolescence. Adv Exp Med Biol. 2013;764:109–22.PubMedGoogle Scholar

  • [15]

    Finethy R, Coers J. Sensing the enemy, containing the threat: cell-autonomous immunity to Chlamydia trachomatis. FEMS Microbiol Rev. 2016;40(6):875–893.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [16]

    Ragland SA, Schaub RE, Hackett KT, Dillard JP, Criss AK. Two lytic transglycosylases in Neisseria gonorrhoeae impart resistance to killing by lysozyme and human neutrophils. Cell Microbiol. 2017;19(3). DOI: .CrossrefWeb of SciencePubMedGoogle Scholar

  • [17]

    Yang XJ. Telocytes in inflammatory gynaecologic diseases and infertility. Adv Exp Med Biol. 2016;913:263–85.CrossrefPubMedGoogle Scholar

  • [18]

    Goodwin K, Fleming N, Dumont T. Tubo-ovarian abscess in virginal adolescent females: a case report and review of the literature. J Pediatr Adolesc Gynecol. 2013;26(4):e99–102.CrossrefPubMedGoogle Scholar

  • [19]

    Simpson-Camp L, Richardson EJ, Alaish SM. Streptococcus viridans tubo-ovarian abscess in an adolescent virgin. Pediatr Int. 2012;54(5):706–9.CrossrefWeb of ScienceGoogle Scholar

  • [20]

    Kielly M, Jamieson MA. Pelvic inflammatory disease in virginal adolescent females without tubo-ovarian abscess. J Pediatr Adolesc Gynecol. 2014;27(1):e5–7.PubMedCrossrefGoogle Scholar

  • [21]

    Cromwell PF, Risser WL, Risser JM. Prevalence and incidence of pelvic inflammatory disease in incarcerated adolescents. Sex Transm Dis. 2002;29(7):391–6.PubMedCrossrefGoogle Scholar

  • [22]

    Campbell R. The psychological impact of rape victims. Am Psychol. 2008;63(8):702–17.PubMedCrossrefGoogle Scholar

  • [23]

    Forsyth S, Rogstad K. Sexual health issues in adolescents and young adults. Clin Med (Lond). 2015;15(5):447–51.CrossrefGoogle Scholar

  • [24]

    Coker TR, Austin SB, Schuster MA. The health and health care of lesbian, gay, and bisexual adolescents. Annu Rev Public Health. 2010;31:457–77.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [25]

    Patel A, DeLong G, Voigl B, Medina C. Pelvic inflammatory disease in the lesbian population – lesbian health issues: asking the right questions. Obstet Gynecol. 2000;4(Suppl 1):S29–30.Google Scholar

  • [26]

    Stahl MA, Greydanus DE, Truba N, Cates K, Pratt HD. Lesbian, gay, bisexual, and transgender and sexuality. In: Merrick J, Greydanuss DE, editors. Sexuality: some international aspects. New York: Nova Science; 2016. p. 91–108.Google Scholar

  • [27]

    Sperry JA. Results following operative treatment of pelvic inflammatory disease in the Stanford University clinic. Cal State J Med. 1918;16(8):388–91.PubMedGoogle Scholar

  • [28]

    Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015; 372(21):2039–48.CrossrefPubMedGoogle Scholar

  • [29]

    Loeper N, Graspeuntner S, Rupp J. Microbiota changes impact on sexually transmitted infections and the development of pelvic inflammatory disease. Microbes Infect. 2018. pii: S1286-4579(18)30047-9.Web of SciencePubMedGoogle Scholar

  • [30]

    Chen JZ, Gratrix J, Smyczek P, Parker P, Read R, Singh AE. Gonococcal and chlamydial cases of pelvic inflammatory disease at 2 Canadian sexually transmitted infection clinics, 2004 to 2014; a retrospective cross-sectional review. Sex Transm Dis. 2018;45(4):280–2.Web of SciencePubMedGoogle Scholar

  • [31]

    Allen M. Identifying acute cervicitis in an era of less-frequent routine gynecologic examinations. JAAPA. 2018;31(2):50–3.Web of ScienceCrossrefGoogle Scholar

  • [32]

    Seña AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, et al. A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among young, asymptomatic high-risk women in the United States. Clin Infect Dis. 2018;67:73–9.CrossrefWeb of SciencePubMedGoogle Scholar

  • [33]

    Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak DB, et al. Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study. Clin Infect Dis. 2018;66(3):437–43.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [34]

    Davies B, Turner KME, Benfield T, Frølund M, Andersen B, Westh H, et al. Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: a retrospective cohort. PLoS Med. 2018;15(1):e1002483.Web of ScienceGoogle Scholar

  • [35]

    Sahu R, Verma R, Dixit S, Igietseme JU, Black CM, Duncan S, et al. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles. Expert Rev Vaccines. 2018;17(3):217–27.PubMedCrossrefWeb of ScienceGoogle Scholar

About the article

Published Online: 2018-11-13


Citation Information: International Journal of Adolescent Medicine and Health, 20180216, ISSN (Online) 2191-0278, DOI: https://doi.org/10.1515/ijamh-2018-0216.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in